Manufacturing: Page 2
-
Stock via Getty Images
Strangers in a strange land: 8 unlikely companies making plays in pharma
How these consumer and service companies are tapping into major trends in the biopharma industry.
By Karissa Waddick • May 22, 2023 -
Permission granted by Patricia Hurter
ProfileA day in the life of a pharma exec: Lyndra’s Patricia Hurter
How the CEO starts each day with a ride on one of her horses, reduces daily meetings and uses her network to get through crises like the SVB Bank collapse.
By Meagan Parrish • May 17, 2023 -
Explore the Trendline➔
Stock via Getty Images
TrendlineCell and gene therapies
How the industry is overcoming hurdles in cell and gene therapy space and pushing for the next generation of treatments.
By PharmaVoice staff -
Stock via Getty Images
Where one unicorn struggled, another biotech is aiming for a diabetes win
Intarcia looked poised to break into a lucrative diabetes implant market but has been dogged by safety issues — now Vivani thinks it’s found a way to succeed.
By Kelly Bilodeau • April 10, 2023 -
alvarez via Getty Images
Staff shortages cause slowdowns in booming cell and gene therapy market
New reports highlight the need for more targeted biotech education curriculums to shore up a sustainable workforce.
By Karissa Waddick • April 3, 2023 -
Stock via Getty Images
Q&A // Biotech SpotlightGracell Biotechnologies’ quest to unlock the CAR-T bottleneck
The biotech hopes to upend the CAR-T category by cutting manufacturing from weeks to hours and developing a first-line cell therapy.
By Taren Grom • Jan. 9, 2023 -
Stock via Getty Images
OpinionThe 2023 PharmaVoice Crystal Ball: Peering into the future of life sciences
A preview of the top trends on the minds of industry and market leaders for the new year.
By Taren Grom • Jan. 3, 2023 -
Permission granted by CSL
Q&AA historic approval could transform CSL from being ‘the biggest company no one has ever heard of’
The company’s head of R&D on its profile-raising FDA approval of a gene therapy that’s now the world’s most expensive drug.
By Meagan Parrish • Dec. 6, 2022 -
Amornrat Phuchom via Getty Images
While CAR-T wait times remain ‘heartbreaking,’ researchers push for innovations that could help
Facing an unprecedented manufacturing bottleneck, a new coalition is aiming to create the next generation of CAR-T therapies.
By Michael Gibney • Nov. 8, 2022 -
Sean Gallup / Staff via Getty Images
How Europe’s energy crisis is impacting pharma
Inflationary pressures and rising energy costs could further expedite the movement of generics manufacturing from Europe to Asia if governments don’t step in.
By Karissa Waddick • Nov. 2, 2022 -
Permission granted by Phil Inc.
Sponsored by Phil, Inc.Developing a channel strategy that optimizes gross to net
Today, pharma manufacturers face unprecedented GTN challenges. To unlock sustainable brand growth, a value-aligned channel strategy is pivotal.
Oct. 31, 2022 -
Permission granted by Doug Langa
Backed by celebrity interest, Novo is finding new success in weight loss — while staying true to its roots
The company's head of U.S. and Canadian operations explains how it’s evolving its game plan after 100 years in the insulin space.
By Meagan Parrish • Oct. 25, 2022 -
Stock via Getty Images
5 impactful drug trial failures from the last year
Major recent trial flops and what they mean for companies, patients and the industry.
By Meagan Parrish • Oct. 19, 2022 -
iStock via Getty Images
Making MovesC-suite shake-ups at 23andMe, Moderna signal new stages of growth
With their latest personnel moves, these life sciences companies are preparing for major business shifts.
By Karissa Waddick • Oct. 5, 2022 -
Stock via Getty Images
Q&AIt’s electric — speeding up the cell therapy process for scalability
To improve the development of cell therapy-based treatments, many companies are turning to a technology that uses electric fields.
By Alexandra Pecci • Oct. 4, 2022 -
Md Saiful Islam Khan via Getty Images
Feds could soon bring COVID-style fight to superbug threat
COVID-19 has inspired renewed urgency in the need for weapons to combat antimicrobial resistant infections and new hope of government funding to meet the challenge.
By Karissa Waddick • Sept. 13, 2022 -
Stock via Getty Images
4 ways to nail the launch of your cell therapy
A consultant’s view on how pharma companies should approach patient experience challenges when rolling out an autologous cell therapy.
By Meagan Parrish • Aug. 10, 2022 -
Mario Tama via Getty Images
The ‘alarming’ spread of Monkeypox — by the numbers
With vaccine and treatment supplies constrained, the virus is becoming ‘less predictable.’
By Meagan Parrish • Aug. 8, 2022 -
Ivan Balvan via Getty Images
Making MovesEditas, Real Chemistry and Compass blaze new trails with pivotal C-suite hires
How these latest executive personnel changes are impacting the industry.
By Karissa Waddick • Aug. 3, 2022 -
Permission granted by Catherine Owen.
Q&AA glimpse inside Bristol Myers Squibb’s integration with Celgene
Catherine Owen, senior vice president of major markets, discusses the hurdles — and successes — of bringing the two ‘powerhouses’ together.
By Meagan Parrish • Aug. 1, 2022 -
Permission granted by John LaMattina
Pfizer's former R&D head takes on drug pricing misconceptions in new book
John LaMattina has something to say about the industry — and he hopes patients are listening.
By Meagan Parrish • July 19, 2022 -
Stock via Getty Images
Q&A // First 90 DaysAnjarium Biosciences’ CEO on its next-gen gene therapies
Stephen Yoo aims to build on the buzz around the company’s leading-edge gene therapy tech.
By Kim Ribbink • July 15, 2022 -
Stock via Getty Images
Q&AThe CEO of Dr. Reddy's N. America is using 'controlled explosions' to keep the generics giant growing
Marc Kikuchi weighs in on the company’s plans to pump up its pipeline and sales in the coming years.
By Meagan Parrish • July 7, 2022 -
Permission granted by David Ross/Seqirus.
Dave Ross of Seqirus talks 'milestone' influenza vax vote
In a unanimous decision, a CDC committee calls for a preferential flu vaccine recommendation for people aged 65 and older for the first time.
By Alexandra Pecci • July 5, 2022 -
Stock via Getty Images
Q&A // Biotech SpotlightBiotech spotlight: Twist Bioscience aims to remove limits on drug discovery with DNA synthesis platform
As ‘the Amazon of DNA,’ Twist CSO, Aaron Sato, discusses the company’s breakthrough approach to DNA production and its expansion into drug development.
By Kim Ribbink • June 30, 2022 -
iStock via Getty Images
Q&AWhy biomanufacturing is the next innovation frontier for genomic therapies
While cell and gene therapy research has accelerated quickly, manufacturing in the space hasn’t quite kept up, Danaher’s Chief Science Officer JC Gutiérrez-Ramos says.
By Meagan Parrish • June 13, 2022
Previous
